Navigation Links
GTG Announces New Product Collaboration with Global Pharmaceutical Company for Companion Diagnostics in Oncology
Date:4/19/2011

VICTORIA, Australia, April 19, 2011 /PRNewswire/ -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE) has executed a preliminary research collaboration agreement to jointly develop a new cancer profiling product with one of the world's leading pharmaceutical companies.

Under the collaboration Genetic Technologies will use certain expertise and intellectual property to work with this world-leading pharmaceutical company to develop specific and novel genetic oncology profiling systems for the targeting of chemotherapy in late stage cancer patients.

GTG will collaborate in a clinical oncology study and provide these results to its collaboration partner. The details of the collaboration and the identity of the counterparty are confidential. This stage of the project is expected to last some months after which time the parties will assess progress and discuss moving to further investigations.

Genetic Technologies' Chief Executive Officer Dr Paul MacLeman said: "GTG's expertise in genetic profiling is widely respected. This collaboration is a validation of GTG's capabilities in the area of very low signal to noise nucleic acid analysis, and we look forward to working with one of the most successful pharmaceutical companies in the world."

"This research collaboration is expected to further embed GTG's franchise in oncology testing and we expect ultimately to lead to better patient outcomes. The need for companion diagnostics to determine effective treatments for cancer patients is well established. We are very excited by this collaboration as we continue to expand our presence in the field of personalized medicine."

About Genetic Technologies LimitedGenetic Technologies was an early pioneer in recognizing important new applications for "non-coding" DNA (Deoxyribonucleic Acid).  The Company has since been granted patents in 24 countries around the world, securing intellectual property rights for particular uses of non-coding DNA in genetic analysis and gene mapping across all genes in all species.  Its business strategy is the global commercialization of its patents through an active out-licensing program and the global expansion of its oncology and cancer management diagnostics portfolio. Genetic Technologies is an ASX and NASDAQ listed company with operations in the USA and Australia. For more information, please visit www.gtglabs.com.

Safe Harbor StatementAny statements in this press release that relate to the Company's expectations are forward-looking statements, within the meaning of the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and  of 1995. Since this information may involve risks and uncertainties and are subject to change at any time, the Company's actual results may differ materially from expected results. Additional risks associated with Genesis Bioventures' business can be found in its periodic filings with the SEC.ENQUIRIESDr Paul D R MacLeman

Rudi Michelson (Australia)

Seth Lewis (USA)Chief Executive Officer

Monsoon Communications

Trout Group Inc.Genetic Technologies Limited

(03) 9620 3333

(646) 378 2952Phone: +61 3 8412 7000
'/>"/>

SOURCE Genetic Technologies Limited
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Sangart Announces Closing of $50 Million Series G Financing
2. MiMedx Group, Inc. Announces Release Date for First Quarter Results
3. Awarepoint Corporation Announces Acquisition of PCTS
4. Omeros Announces Publication of MASP-2 Data in Proceedings of the National Academy of Sciences
5. Cumberland Pharmaceuticals Announces New Product Addition With Hepatoren™ (ifetroban) Injection
6. CryoLife Announces Release Date and Teleconference Call Details for 2011 First Quarter Financial Results
7. Amicus Therapeutics Announces Transition of John F. Crowley from Chairman and Chief Executive Officer to Executive Chairman
8. American Scientific Resources, Inc. Announces Corporate Update
9. Sigma-Tau Pharmaceuticals Announces Approval for New Manufacturing Process for ONCASPAR® (Pegaspargase) Primary Ingredient
10. CryoLife Announces Expiration of Go-Shop Period Related to its Proposed Acquisition of Cardiogenesis Corporation
11. Keryx Biopharmaceuticals Announces Commencement of Phase 3 Program of Ferric Citrate (Zerenex™) in Japan by Partner, Japan Tobacco and Torii Pharmaceutical
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... Research and Markets has announced the addition of the ... Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2014 ... ... US$ 7,167.6 Mn in 2015, and is expected to reach ... 5.6% from 2016 to 2024. The global ...
(Date:4/19/2017)... /PRNewswire/ - CRH Medical Corporation (TSX: CRH) (NYSE MKT: CRHM) (the "Company"), announces ... Investor Conference 2017 at the Sheraton Hotel in Toronto, ... Officer of the Company is scheduled to present on Tuesday, May ... and the Chairman of the Board, Tony Holler will ... For ...
(Date:4/19/2017)... 2017 Global Surgical Drainage Device Market: Overview ... to remove excess liquid and air. The fluid to ... or lymph. Surgical drains are used in a wide ... surgery, cardiovascular surgery, neurosurgery, plastic surgery etc. Common use ... accumulation of fluid e.g. blood or pus. Surgical drains ...
Breaking Medicine Technology:
(Date:4/25/2017)... ... April 25, 2017 , ... A recent report ... score performance for the 2015-16 school year across Wisconsin’s public schools, charter schools, ... highlights important patterns in student test score performance, the report’s limited analyses fail ...
(Date:4/25/2017)... ... April 25, 2017 , ... ... on contracted partners to help with process innovation in drug formulation and manufacturing. ... experience along with state-of-the-art analytical equipment in support of their development and manufacturing ...
(Date:4/25/2017)... ... 2017 , ... Saad B. Chaudhary, MD is committed to providing the highest quality of spine ... focus on preventative care with all my patients to alleviate possible future issues. I am ... to contact my office and my trained staff will assist you in any way possible.” ...
(Date:4/25/2017)... ... April 25, 2017 , ... ... healthcare products, is introducing Flexadin UCII, part of the EQUISTRO line, at this ... joint health in horses at the immunologic level. , The scientifically-developed Flexadin UCII ...
(Date:4/24/2017)... ... 24, 2017 , ... Michael Vick announced his retirement earlier this year from ... overall number one pick in the 2001 NFL Draft, to the Atlanta Falcons, made ... the most career rushing yards by a quarterback (6,109) and the most rushing yards ...
Breaking Medicine News(10 mins):